Intricon has named Dave Liebl as its first Chief Commercial and Technology Officer (CCO/CTO).
“The new role is essential as we enhance our commercial growth strategy. Dave’s commercial experience makes him an ideal leader for Intricon’s next phase of growth and development,” said Scott Longval, president and chief executive officer of Intricon. “In Dave’s expanded role, he is responsible for accelerating our innovation roadmap and expanding our customer relationships.”
Dave’s career includes more than 25 years of business development, engineering, and product development experience at multiple high technology and medical technology companies. Prior to joining Intricon in August 2021 as vice president of research and development, Dave served as the president of Biomerics NLE’s West Operations. Prior to his role at Biomerics, he held several roles at Heraeus Medical Components/NeoMetrics, Inc., including EVP, product and business development, president and chief technology officer, and VP of development, spanning from 2005 to 2019. His career also includes director and vice president level positions at Pearson, Datacard Group, and MedAmicus, Inc. (now part of Integer Holdings).
“Intricon has a strong foundation of core competencies and technologies, which are well positioned to meet the needs of industry trends. Further, our global manufacturing footprint enables us to meet customer cost targets,” said Dave. “I’m looking forward to pursuing opportunities in high-growth markets by advancing our technology and commercial operations to meet and exceed our customers’ expectations.”